ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children (H1N1Children)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01097941
Recruitment Status : Withdrawn (Live H1N1 vaccine expired and unable to get new supply)
First Posted : April 2, 2010
Last Update Posted : September 24, 2015
Sponsor:
Collaborator:
National Institutes of Health (NIH)
Information provided by (Responsible Party):
John Treanor, University of Rochester

Brief Summary:
A total of 51 children between the ages of 4 and 9 will be randomized to receive a two dose schedule of either licensed live attenuated A/California/07/09 influenza vaccine (LAIV) or licensed inactivated A/California/07/09 influenza vaccine (IIV) or IIV followed by LAIV separated by 28 days. Children with prior vaccination or natural infection with novel H1N1 influenza will be excluded. Randomization will be stratified by pre-existing HAI titers to the previous winter's seasonal H1N1 A/Brisbane/57/07 reference virus.

Condition or disease Intervention/treatment Phase
2009 H1N1 Influenza Biological: Live Attenuated H1N1 Influenza Vaccine Biological: Influenza A (H1N1) 2009 Monovalent Vaccine Biological: Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live Phase 4

Detailed Description:

The study will be conducted as a randomized, prospective, open-label evaluation of the clinical tolerability, vaccine virus shedding, and serum and mucosal antibody response to vaccination with either live monovalent novel H1N1 influenza vaccine (LAIV) or monovalent inactivated novel H1N1 influenza vaccine (IIV) in healthy children between the ages of 4 and 9 years. Children will be screened for antibody to A/Brisbane/57/07 (H1N1) and A/California/07/09 (H1N1) prior to randomization. Children with evidence of prior exposure to the 2009 pandemic H1N1 virus will be excluded. Those with antibodies to A/Brisbane/57/07 (H1N1) will be stratified by preexisting antibody. Vaccine will be administered on days 0 and 28.

Safety of vaccination will be assessed using symptoms collected by parents for 7 days after each dose of vaccine. Serum will be obtained prior to and on day 28 following each dose of vaccine and assessed for antibody by HAI, ELISA, B-cell ELISPOT and neutralization techniques. Nasal secretions will be obtained by nasal aspiration prior to and on day 28 after each dose and assessed for HA-specific IgA antibody by ELISA. Nasal swabs will be obtained on days 2, 4, and 7 after each dose of live vaccine and assessed for the presence and magnitude of vaccine virus shedding of the live attenuated vaccine by rtRT-PCR and TCID50 on MDCK cells.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of the Effect of Age and Prior Immunity on the Response to Live or Inactivated A/California/07/09 H1N1 Influenza Vaccines in Children
Study Start Date : March 2010
Actual Primary Completion Date : September 2010
Actual Study Completion Date : September 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Flu Flu Shot
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: LAIV/LAIV Biological: Live Attenuated H1N1 Influenza Vaccine
0.2 ml dose of live monovalent vaccine delivered through nasal spray, 2 doses given 28 days apart
Other Name: Influenza A (H1N1) 2009 Monovalent Vaccine Live, Intranasal
Active Comparator: IIV/IIV Biological: Influenza A (H1N1) 2009 Monovalent Vaccine
0.5 ml IM, 2 doses given 28 days apart
Other Name: Influenza vaccine
Active Comparator: IIV/LAIV Biological: Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live
0.5 ml IM given X1 with 0.1 ml intranasally given 28 days later
Other Name: Influenza Vaccine



Primary Outcome Measures :
  1. The primary endpoint for assessment of the live attenuated vaccine take will be the AUC of the live vaccine virus shedding determined by 50% tissue culture infectious dose (TCID ) on MDCK cells at 33 degrees C [ Time Frame: nasal swabs obtained at days 2 post vaccination ]
  2. The primary endpoint for assessment of the live attenuated vaccine take will be the AUC of the live vaccine virus shedding determined by 50% tissue culture infectious dose (TCID ) on MDCK cells at 33 degrees C [ Time Frame: nasal swab at 4 days post vaccination ]
  3. The primary endpoint for assessment of the live attenuated vaccine take will be the AUC of the live vaccine virus shedding determined by 50% tissue culture infectious dose (TCID ) on MDCK cells at 33 degrees C [ Time Frame: nasal swab obtained at 7 days post vaccination ]

Secondary Outcome Measures :
  1. The AUC of nasopharyngeal shedding assessed by quantitative rtRT-PCR [ Time Frame: swabs will be obtained on day 2 post vaccination ]
  2. The frequency and magnitude of serum hemagglutination-inhibition (HAI), ELISA, and neutralizing antibody response to vaccine [ Time Frame: at day 28 ]
  3. The frequency and magnitude of hemagglutinin-specific mucosal IgA response assessed by ELISA on nasal secretions [ Time Frame: day 28 ]
  4. The frequency and magnitude of antibody secreting cell and memory B cells developing after vaccination [ Time Frame: on day 7 ]
  5. Development of specific local and systemic symptoms occuring after vaccine [ Time Frame: for 7 days post each vaccination ]
  6. The AUC of nasopharyngeal shedding assessed by quantitative rtRT-PCR [ Time Frame: swab obtained at day 4 post vaccination ]
  7. The AUC of nasopharyngeal shedding assessed by quantitative rtRT-PCR [ Time Frame: swab obtained at day 7 post vaccination ]
  8. The frequency and magnitude of serum hemagglutination-inhibition (HAI), ELISA, and neutralizing antibody response to vaccine [ Time Frame: at day 56 ]
  9. The frequency and magnitude of hemagglutinin-specific mucosal IgA response assessed by ELISA on nasal secretions [ Time Frame: at day 56 ]
  10. The frequency and magnitude of antibody secreting cell and memory B cells developing after vaccination [ Time Frame: on day 35 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   4 Years to 9 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Aged between 4 and 9 years, inclusive.
  • Pre-vaccination serum HAI titer to A/California/07/09 of 8 or less
  • No prior history of laboratory documented infection with novel H1N1 virus or immunization with novel H1N1 vaccine.
  • in good health, as determined by: vital signs (heart rate <140 bpm; blood pressure: systolic ≥ 90 mm Hg and ≤140 mm Hg; diastolic ≤ 90 mm Hg; oral temperature <100.0ºF); medical history; and targeted physical examination, when necessary, based on medical history. Stable medical condition is defined as: no recent increase in prescription medication, dose, or frequency of medication in the last 3 months and health outcomes of the specific disease are considered to be within acceptable limits in the last 6 months.
  • subject/parents are able to understand and comply with the planned study procedures, including being available for all study visits.
  • subject/parents have provided informed consent prior to any study procedures. (An assent will be obtained for all children 6 years and older)

Exclusion Criteria:

  • a previous history of vaccination against novel H1N1 virus or a laboratory documented history of previous novel H1N1 infection.
  • History of egg allergy or allergy to other components of vaccine.
  • History of wheezing.
  • immunosuppressed as a result of an underlying illness or treatment with immunosuppressive or cytotoxic drugs, or use of anticancer chemotherapy or radiation therapy.
  • has an active neoplastic disease.
  • has long-term (greater than 2 weeks) use of oral or parenteral steroids, or high-dose inhaled steroids (>800 mg/day of beclomethasone dipropionate or equivalent) within the preceding 6 months (nasal and topical steroids are allowed).
  • received immunoglobulin or another blood product within the 3 months prior to enrollment in this study.
  • has received an inactivated vaccine within the 2 weeks or a live vaccine within the 4 weeks prior to enrollment in this study or plans to receive another vaccine within the next 28 days (or 56 days for vaccine naïve recipients).
  • has an acute or chronic medical condition that, in the opinion of the investigator, would render vaccination unsafe or would interfere with the evaluation of responses. These conditions include chronic conditions recognized as risk factors for influenza complications or as contraindications for live vaccination, including chronic cardiac (exclusive of hypertension) or pulmonary conditions (including asthma), diabetes mellitus, or renal impairment.
  • has an acute illness or an oral temperature greater than 99.9 degrees F (37.7 degrees C) within 3 days prior to enrollment or vaccination. Subjects who had an acute illness that was treated symptoms resolved are eligible to enroll as long as treatment is completed and symptoms resolve > 3 days prior to enrollment.
  • is currently participating or plans to participate in a study that involves an experimental agent (vaccine, drug, biologic, device, blood product, or medication) or has received an experimental agent within 1 month prior to enrollment in this study, or expects to receive another experimental agent during participation in this study, or intends to donate blood during the study period.
  • has any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.
  • has a known human immunodeficiency virus, hepatitis B, or hepatitis C infection.
  • has a previous history of Guillain-Barré syndrome within 6 weeks of receipt of influenza vaccination.
  • has any condition that the principal investigator (PI) believes may interfere with successful completion of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01097941


Locations
United States, New York
University of Rochester Medical Center, Vaccine Research Unit Room 3-5000
Rochester, New York, United States, 14642
Sponsors and Collaborators
University of Rochester
National Institutes of Health (NIH)
Investigators
Principal Investigator: John J Treanor, MD University of Rochester

Publications:

Responsible Party: John Treanor, Professor, University of Rochester
ClinicalTrials.gov Identifier: NCT01097941     History of Changes
Other Study ID Numbers: URMC 09-007
First Posted: April 2, 2010    Key Record Dates
Last Update Posted: September 24, 2015
Last Verified: September 2015

Keywords provided by John Treanor, University of Rochester:
Influenza
H1N1

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases
Vaccines
Immunologic Factors
Physiological Effects of Drugs